For example, it is estimated that more than 40% of NSCLC cases with EGFR Exon 20 insertions (ex20ins) may be undetected by the cobas EGFR test compared to NGS-based genetic testing [18,19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.